Suchergebnisse - (Subject:"O3J8G9O825")

PubPharm (1.712)

51

Health-related quality-of-life in people living with HIV after switching to dual therapy with ritonavir-boosted darunavir + dolutegravir : a DUALIS sub-study

enthalten in: AIDS care | 2022

von Olliges, E. | Bührlen, B. | Fischer, F. | +14

52

Improvement in Bioavailability and Pharmacokinetic Characteristics of Efavirenz with Booster Dose of Ritonavir in PEGylated PAMAM G4 Dendrimers

enthalten in: AAPS PharmSciTech | 2022

von Kharwade, R. | More, S. | Suresh, E. | +3

53

The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells : a Dose Escalation Study

enthalten in: Antimicrobial agents and chemotherapy | 2022

von De Nicolò, A. | Calcagno, A. | Motta, I. | +8

54

Analysis of virological response to therapy and resistance profile in treatment-experienced and naive HIV-1 infected Romanian patients receiving regimens containing darunavir boosted with ritonavir or cobicistat

enthalten in: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | 2022

von Marin, R. | Streinu-Cercel, A. | Moleriu, L. | +1

55

Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings : ACTG A5288 strategy trial

enthalten in: Journal of the International AIDS Society | 2022

von Avihingsanon, A. | Hughes, M. | Salata, R. | +31

56

Pharmacokinetics, metabolism and excretion of radiolabeled fostemsavir administered with or without ritonavir in healthy male subjects

enthalten in: Xenobiotica; the fate of foreign compounds in biological systems | 2022

von Gorycki, P. | Magee, M. | Ackerman, P. | +2

57

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA) : week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial

enthalten in: The lancet. HIV | 2022

von Paton, N. | Musaazi, J. | Kityo, C. | +101

CommentIn: Lancet HIV. 2022 Jun;9(6):e368-e369. - PMID 35460602

58

Exposure of human immune cells, to the antiretrovirals efavirenz and lopinavir, leads to lower glucose uptake and altered bioenergetic cell profiles through interactions with SLC2A1

enthalten in: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | 2022

von Heaton, B. | Jensen, R. | Line, J. | +4

59

Quality of life and associated factors among people receiving second-line anti-retroviral therapy in Johannesburg, South Africa

enthalten in: BMC infectious diseases | 2022

von Mokgethi, N. | Christofides, N. | Machisa, M. | +2

60

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants

enthalten in: Antimicrobial agents and chemotherapy | 2022

von Moore, K. | Thakkar, N. | Magee, M. | +5